https://www.selleckchem.com/pr....oducts/Vorinostat-sa
), NDVH 0 (0-1), TLH 0 (0-2), p = 0.56], urinary voiding symptoms [TAH 0 (0-, NDVH 0 (0-, TLH 0 (0-, p = 0.64] and urinary incontinence symptoms [TAH 0 (0-, NDVH 0 (0-1), TLH 0 (0-1), p = 0.35] at 1-year. Conclusions There was a post-operative improvement in vaginal symptoms and urinary symptoms in all three groups. There was no significant difference in pelvic organ symptoms between the three routes; TAH, NDVH and TLH. Trial registration Sri Lanka clinical trials registry, SLCTR/2016/020 and the International Clinical T
إعجاب
علق
شارك
